PBM Reform

PDABs say they’re helping patients. In reality, they’re muzzling public input and playing politics with life-saving medications.

Copay accumulator policies make patients pay twice. It's 2025, and insurers are still profiting while patients go broke.

The FTC confirms PBMs are price-gouging specialty generics, raking in billions while blocking patient access to life-saving meds.

Congress faces urgent healthcare decisions before 2025—telehealth, CHC funding, and physician payments hang in the balance during lame duck.